NHS Trust Approves UK-First Inpatient Medical Cannabis Policy

Policy Fills Eight-Year Gap in NHS Inpatient Care

The policy establishes protocols for storage, administration, and clinical oversight of medical cannabis prescriptions during hospital admission. Since the UK legalized cannabis-based medicinal products in 2018, no standardized NHS framework existed for managing these medications in inpatient settings, according to cannabishealthnews.co.uk. Patients have routinely been required to discontinue treatment upon admission. This happens even when cannabis was prescribed for epilepsy, chronic pain, or other conditions where interruption carries clinical risk.

Years of advocacy by patient groups and clinicians documented treatment disruptions and adverse outcomes tied to forced cessation. The trust's approval follows that pressure.

NHS Framework Addresses Storage and Controlled-Drug Compliance

The policy designates medical cannabis as a Schedule 2 controlled drug under UK law, requiring secure storage and dual-signature protocols. Hospital pharmacies will verify prescriptions issued by General Medical Council-registered specialists, store products in controlled-drug cabinets, and maintain administration logs identical to those used for morphine and other Schedule 2 substances.

Nursing staff will administer cannabis oils, capsules, or vaporized products according to the patient's existing prescription. New cannabis prescriptions can't be initiated during inpatient care. The policy applies only to continuation of pre-admission treatment.

Specialist Prescribers and GMC Registration Required

Only cannabis prescriptions issued by GMC-registered specialists on the General Medical Council's specialist register qualify under the policy. Private telemedicine prescriptions issued by non-specialist physicians don't make the cut—a common pathway for UK medical cannabis access. The trust's policy aligns with NHS England guidance limiting cannabis prescriptions to specialists in neurology, pain medicine, palliative care, and pediatrics.

Patients whose prescriptions don't meet the specialist-registration requirement will continue to face treatment interruption during admission.

Epilepsy and Chronic Pain Patients Stand to Benefit Most

Patients with treatment-resistant epilepsy and severe chronic pain are the policy's primary beneficiaries, conditions for which cannabis-based medicinal products have the strongest evidence base under UK regulatory guidance. Epidiolex, a CBD isolate, and Sativex, a THC-CBD oromucosal spray, are the only cannabis products approved for NHS prescription. Unlicensed whole-plant extracts may be prescribed by specialists under exceptional circumstances, though they're rare.

Patient advocacy organizations estimate that several thousand UK patients hold valid specialist prescriptions. The majority access cannabis through private clinics rather than NHS pathways.

Trust Identity and Implementation Timeline Not Disclosed

The NHS trust that approved the policy hasn't been publicly identified, and no implementation date has been announced. Cannabishealthnews.co.uk reported the approval without naming the trust or specifying whether the policy is operational. NHS trusts operate with regional autonomy. A policy adopted by one trust doesn't automatically extend to others.

Patients admitted to hospitals outside the adopting trust's catchment area won't benefit from the policy, given the lack of national standardization.

National Policy Debate Likely to Intensify

This approval will likely accelerate calls for NHS England to issue national guidance on inpatient medical cannabis management. The Royal College of Physicians and the British Pain Society have both called for standardized protocols, citing patient-safety concerns tied to abrupt discontinuation of cannabinoid therapy.

For full background on this story, see the CannIntel topic hub on UK Medical Cannabis Policy. The next signal: whether NHS England adopts the trust's framework as a national template or leaves policy to regional discretion.